Xiang Zhu

Xiang Zhu

Auto-generated profile, based on publicly available information

Xiang Zhu

Department of Pathology, Peking University Third Hospital, Beijing 100191, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
ZFZhongyi Fan
Zhongyi Fan
JYJing Yang
Jing Yang
DZDong Zhang
Dong Zhang
Xuelin ZhangXuelin Zhang
Xuelin Zhang
XMXiaoyan Ma
Xiaoyan Ma
SJShunchang Jiao
Shunchang Jiao

1 January 2020 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
PDF file
XZXiang Zhu
Xiang Zhu
YCYe Cheng
Ye Cheng
FWFan Wu
Fan Wu
HSHaoyao Sun
Haoyao Sun
WZWubin Zheng
Wubin Zheng
HCHongyong Cao
Hongyong Cao
Backgrounds: Microfibril-associated protein 2 (MFAP2) is an extracellular matrix protein that regulates the function of microfibrils by interacting with fibrillin. MFAP2 has been reported to play an important role in metabolic diseases and has been shown to be significantly overexpressed in head and neck squamous cell carcinoma and Hepatocellular carcinoma (HCC). However, the molecular function and prognostic value of MFAP2 have never been reported in HCC or other tumors. Methods: In the present study, expression characteristics of MFAP2 in HCC, its influence on the development of HCC, as well as its function and potential mechanism in HCC were verified by Quantitative reverse transcription-polymerase chain reaction, bioinformatics data mining and in vitro cell experiments. Results: MFAP2 was prominently high-expressed in HCC and associated with cancer stages. HCC patients with higher MFAP2 expression displayed lower overall survival (OS) and disease-specific survival(DSS), while there was no significant difference in recurrence-free survival (RFS). In vitro experiments showed that downregulation of MFAP2 inhibited proliferation, migration level of HCC cells. Transcription factors, DNA methyltransferases, immune factors may interact with MFAP2 mRNA to promote tumor progression in HCC. Conclusion: These findings suggest that MFAP2 may play a key role in the development of HCC. Therefore, MFAP2 may be a valuable prognostic marker and an effective anticancer target in HCC.

1 March 2014
Verified
Journal Article
Open access
PDF file
XZXiang Zhu
Xiang Zhu
HLHongwei Bran Li
Hongwei Bran Li
BCBaoshan Cao
Baoshan Cao
CLChen Liu
Chen Liu
LLLiang Li
Liang Li
BZBo Zhang
Bo Zhang
Background and objective The fusion (rearrangement) of anaplastic lymphoma kinase (ALK) gene has been identified as an import factor to the tumorigenesis and development of lung cancer. ALK tyrosine kinase inhibitors (ALK-TKIs) have been proved to have good effects to ALK positive lung cancers. The increasement of the relevance ratio of ALK will be very important to patients. The aim of this study is to investigate the clinical pathological features of ALK positive lung cancer, and the roles of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in screening and confirming the ALK positive cases in the testing flow of ALK. Methods IHC analysis of ALK in tumor specimens was performed on 525 lung cancer patients. 34 cases among them were confirmed by FISH. Results The positive incidence of ALK by IHC was 5.14% (27/525). The ALK positive patients were significantly younger than ALK negative patients (P<0.05), and femal was predominant (P<0.05). The proportion of solid predominant adenocarcinoma was significantly higher in ALK positive patients (P<0.05). While acinar and lepidic predominant adenocarcinoma were significantly lower in ALK positive patients (P<0.05). FISH was applied in 34 cases. The coincidence rate was increased with the increasement of positive intensity of IHC staining. All the IHC positive cases with or without EGFR mutation must be confirmed by FISH. Conclusion IHC is a reliable detection method to screening the ALK in lung cancer, and then enhance the relevance ration. To make a definite diagnosis of ALK positive lung cancer, FISH is a significant detection method. DOI: 10.3779/j.issn.1009-3419.2014.03.08

15 June 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MLMing Lu
Ming Lu
XZXiang Zhu
Xiang Zhu
NSNing Shen
Ning Shen

20 March 2020
Verified
Journal Article
Open access
MLMing Lu
Ming Lu
XZXiang Zhu
Xiang Zhu
BCBaoshan Cao
Baoshan Cao
NSNing Shen
Ning Shen
Endotracheal and endobronchial metastases (EEM) is a rare manifestation in primary lung cancer. It has not yet been reported in Chinese literatures. The aim of this study was to summarize and analyze the clinical feature of lung cancer with EEM. We retrospectively reviewed 6 patients who presented with EEM of lung cancer from Peking University Third Hospital from January 2015 to December 2018. With "endotracheal metastases, endobronchial metastases, lung cancer" as the keywords, 13 cases were retrieved from PubMed database until February 2020. The clinical, radiologic and bronchoscopic data were collected. Six patients were selected from 967 patients with lung cancer, and all were diagnosed with lung cancer and EEM simultaneously. There were 4 cases of squamous cell carcinoma, 1 case of adenocarcinoma, and 1 case of small cell lung cancer. One patient had stage IIIb and 5 patients had stage IV. There were 5 cases of central lung cancer and 1 case of peripheral lung cancer. EEM on bronchoscope examination presented as endoluminal nodular or polypoid lesion in 5 patients, and abnormal white bulge in 1 patient. 5 cases metastasized to the contralateral bronchus, 1 case to the ipsilateral bronchus and 1 case to the trachea. The median overall survival was 7.5 months. Totally 13 cases of lung cancer with EEM were retrieved from PubMed database. 12 cases were diagnosed during the follow up after lung cancer resection. There were 8 cases of squamous cell carcinoma and 9 cases of central type. Endotracheal or endobronchial nodules showed in 10 cases and eccentric wall thickening in 2 cases were seen on chest computed tomography (CT), which corresponding to the nodular or polypoid lesion bronchoscopically. 5 cases metastasized to the contralateral bronchus, 10 cases to the trachea and 1 case to the ipsilateral bronchus. EEM is a rare metastasis of lung cancer, which can occur at the initial diagnosis of lung cancer or after surgical resection. It is often seen in the patients of squamous cell carcinoma with central type in advanced stage. The prognosis is poor.

1 March 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JRJeremy D. Rubinstein
Jeremy D. Rubinstein
CLCarolyn Lutzko
Carolyn Lutzko
TLTom Leemhuis
Tom Leemhuis
XZXiang Zhu
Xiang Zhu
LRLorraine Ray
Lorraine Ray
MGMichael S. Grimley
Michael S. Grimley